Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DICER1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DICER1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DICER1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DICER1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DICER1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DICER1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DICER1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DICER1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DICER1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002241118 | Prostate | Tumor | cellular component disassembly | 121/3246 | 443/18723 | 8.10e-08 | 2.23e-06 | 121 |
GO:001072013 | Prostate | Tumor | positive regulation of cell development | 88/3246 | 298/18723 | 1.22e-07 | 3.17e-06 | 88 |
GO:003465516 | Prostate | Tumor | nucleobase-containing compound catabolic process | 112/3246 | 407/18723 | 1.61e-07 | 4.02e-06 | 112 |
GO:004670014 | Prostate | Tumor | heterocycle catabolic process | 117/3246 | 445/18723 | 1.11e-06 | 2.10e-05 | 117 |
GO:004427015 | Prostate | Tumor | cellular nitrogen compound catabolic process | 118/3246 | 451/18723 | 1.30e-06 | 2.39e-05 | 118 |
GO:190136114 | Prostate | Tumor | organic cyclic compound catabolic process | 124/3246 | 495/18723 | 7.37e-06 | 1.10e-04 | 124 |
GO:001943914 | Prostate | Tumor | aromatic compound catabolic process | 118/3246 | 467/18723 | 7.92e-06 | 1.17e-04 | 118 |
GO:005076911 | Prostate | Tumor | positive regulation of neurogenesis | 64/3246 | 225/18723 | 2.26e-05 | 2.88e-04 | 64 |
GO:005076711 | Prostate | Tumor | regulation of neurogenesis | 93/3246 | 364/18723 | 4.45e-05 | 5.02e-04 | 93 |
GO:003806111 | Prostate | Tumor | NIK/NF-kappaB signaling | 42/3246 | 143/18723 | 2.56e-04 | 2.14e-03 | 42 |
GO:005196211 | Prostate | Tumor | positive regulation of nervous system development | 69/3246 | 272/18723 | 4.99e-04 | 3.67e-03 | 69 |
GO:003447013 | Prostate | Tumor | ncRNA processing | 94/3246 | 395/18723 | 6.02e-04 | 4.31e-03 | 94 |
GO:005196011 | Prostate | Tumor | regulation of nervous system development | 102/3246 | 443/18723 | 1.20e-03 | 7.60e-03 | 102 |
GO:004206312 | Prostate | Tumor | gliogenesis | 73/3246 | 301/18723 | 1.35e-03 | 8.46e-03 | 73 |
GO:0045687 | Prostate | Tumor | positive regulation of glial cell differentiation | 15/3246 | 42/18723 | 3.32e-03 | 1.73e-02 | 15 |
GO:00100014 | Prostate | Tumor | glial cell differentiation | 55/3246 | 225/18723 | 4.13e-03 | 2.08e-02 | 55 |
GO:003519613 | Prostate | Tumor | production of miRNAs involved in gene silencing by miRNA | 17/3246 | 52/18723 | 5.24e-03 | 2.52e-02 | 17 |
GO:00140371 | Prostate | Tumor | Schwann cell differentiation | 14/3246 | 40/18723 | 5.52e-03 | 2.61e-02 | 14 |
GO:003105013 | Prostate | Tumor | dsRNA processing | 17/3246 | 54/18723 | 7.97e-03 | 3.52e-02 | 17 |
GO:007091813 | Prostate | Tumor | production of small RNA involved in gene silencing by RNA | 17/3246 | 54/18723 | 7.97e-03 | 3.52e-02 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DICER1 | SNV | Missense_Mutation | novel | c.4430C>G | p.Ser1477Cys | p.S1477C | Q9UPY3 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.733) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
DICER1 | SNV | Missense_Mutation | | c.3037N>A | p.Pro1013Thr | p.P1013T | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
DICER1 | SNV | Missense_Mutation | | c.2326N>T | p.Val776Phe | p.V776F | Q9UPY3 | protein_coding | deleterious(0.02) | probably_damaging(0.979) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DICER1 | SNV | Missense_Mutation | | c.5240N>T | p.Ser1747Leu | p.S1747L | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
DICER1 | SNV | Missense_Mutation | novel | c.1490N>C | p.Glu497Ala | p.E497A | Q9UPY3 | protein_coding | tolerated(0.06) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DICER1 | SNV | Missense_Mutation | | c.2084C>T | p.Ala695Val | p.A695V | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DICER1 | SNV | Missense_Mutation | novel | c.322N>G | p.Gln108Glu | p.Q108E | Q9UPY3 | protein_coding | tolerated(0.59) | benign(0.055) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
DICER1 | SNV | Missense_Mutation | rs752424727 | c.1778C>T | p.Ser593Leu | p.S593L | Q9UPY3 | protein_coding | tolerated(0.2) | benign(0.033) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
DICER1 | SNV | Missense_Mutation | | c.4529N>A | p.Cys1510Tyr | p.C1510Y | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
DICER1 | SNV | Missense_Mutation | | c.4018G>C | p.Glu1340Gln | p.E1340Q | Q9UPY3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |